Published in Gene Therapy Weekly, August 3rd, 2006
"IL-2 used in the treatment of malignant tumors has an anti-tumor efficacy. In this study, we have studied in vitro characterization and transfection efficiency of a plasmid encoding hIL-2, pCXWN-hIL-2, complexed to chitosan, polyethylenimine or DOTAP with varying ratios," wrote G. Ozgel and colleagues, University of Marmara.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.